Land: Australia
Språk: engelsk
Kilde: Department of Health (Therapeutic Goods Administration)
pramipexole dihydrochloride monohydrate, Quantity: 2.25 mg
Arrotex Pharmaceuticals Pty Ltd
pramipexole dihydrochloride monohydrate
Tablet, modified release
Excipient Ingredients: hypromellose; calcium hydrogen phosphate; silicon dioxide; magnesium stearate
Oral
30, 10
(S4) Prescription Only Medicine
For the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa.
Visual Identification: White or nearly white, cylindrical and biconvex tablets marked with 157 on one side.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
2015-06-17
PRAMIPEXOLE XR GP 1 PRAMIPEXOLE XR GP _contains the active ingredient pramipexole dihydrochloride monohydrate _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about PRAMIPEXOLE XR GP. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking PRAMIPEXOLE XR GP against the benefits it is expected to have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, TALK TO YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH YOUR MEDICINE. You may need to read it again. WHAT THIS MEDICINE IS USED FOR PRAMIPEXOLE XR GP is used to treat the symptoms of Parkinson's disease. Parkinson's disease is a disease of the brain that affects body movement. The symptoms of Parkinson's disease are caused by a lack of dopamine, a naturally occurring chemical produced by certain brain cells. Dopamine binds to dopamine receptors and relays messages in the part of the brain that controls movement. When too little dopamine is produced, this results in Parkinson's disease. _HOW IT WORKS _ PRAMIPEXOLE XR GP contains the active ingredient pramipexole dihydrochloride monohydrate, which belongs to a group of medicines known as dopamine agonists, which bind to dopamine receptors. PRAMIPEXOLE XR GP works by having a similar effect as dopamine in the brain. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY PRAMIPEXOLE XR GP HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed PRAMIPEXOLE XR GP for another reason. PRAMIPEXOLE XR GP is not addictive. This medicine is available only with a doctor's prescription. _USE IN CHILDREN _ PRAMIPEXOLE XR GP is not recommended for use in children under 18 years of age as its safety and effectiveness in that age group have not been established. BEFORE YOU TAKE THIS MEDICINE _WHEN YOU MUST NOT TAKE IT _ DO NOT HAVE PRAMIPEXOLE XR GP IF YOU HAVE AN ALLERGY TO: • Any medicine containing pramipexole dihydro Les hele dokumentet
1 AUSTRALIAN PRODUCT INFORMATION PRAMIPEXOLE XR GP (pramipexole dihydrochloride monohydrate) modified release tablets 1 NAME OF THE MEDICINE Pramipexole dihydrochloride monohydrate. 2 & 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM Pramipexole dihydrochloride monohydrate modified release tablets Pramipexole dihydrochloride monohydrate 0.375 mg modified release tablets are white or nearly white, cylindrical, plans and bevel tablets marked with 026 on one side. Each modified release tablet contains 0.375 mg pramipexole dihydrochloride monohydrate. Pramipexole dihydrochloride monohydrate 0.75 mg modified release tablets are white or nearly white, cylindrical and biconvex tablets marked with 052 on one side. Each modified release tablet contains 0.75 mg pramipexole dihydrochloride monohydrate. Pramipexole dihydrochloride monohydrate 1.5 mg modified release tablets are white or nearly white, cylindrical and biconvex tablets marked with 105 on one side. Each modified release tablet contains 1.5 mg pramipexole dihydrochloride monohydrate. Pramipexole dihydrochloride monohydrate 2.25mg modified release tablets are white or nearly white, cylindrical and biconvex tablets marked with 157 on one side. Each modified release tablet contains 2.25mg pramipexole dihydrochloride monohydrate. Pramipexole dihydrochloride monohydrate 3 mg modified release tablets are white or nearly white, cylindrical and biconvex tablets marked with 210 on one side. Each modified release tablet contains 3 mg pramipexole dihydrochloride monohydrate. Pramipexole dihydrochloride monohydrate 3.75mg modified release tablets are white or nearly white, cylindrical and biconvex tablets marked with 262 on one side. Each modified release tablet contains 3.75mg pramipexole dihydrochloride monohydrate. Pramipexole dihydrochloride monohydrate 4.5 mg modified release tablets are white or nearly white, cylindrical, plans and bevel tablets marked with 315 on one side. Each modified release tablet contains 4.5 mg pramipexole dihydrochloride mono Les hele dokumentet